Niagen Bioscience Inc. Expands Availability of Niagen IV Therapy

Los Angeles, May 5, 2025 — Niagen Bioscience, Inc. (Nasdaq: NAGE), a leader in the health care sector specializing in life sciences tools and services, has announced a significant expansion in the availability of its pharmaceutical-grade Niagen® IV therapy. The therapy is now accessible in nearly 600 clinics across the United States, marking a substantial increase in its clinical footprint.

Niagen IV, a patented formulation of nicotinamide riboside (NR), is designed to enhance the body’s levels of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy production and overall health. The company highlights that Niagen IV offers superior tolerability compared to other NAD+ IV therapies, with a 75% shorter infusion time and a 20% higher increase in NAD+ levels three hours post-infusion.

This expansion follows Niagen Bioscience’s commitment to making its NAD+ therapies more widely available, supporting its mission to advance the science of healthy aging. The company’s efforts are part of a broader trend in the health care industry focusing on NAD+ as a critical factor in cellular energy, DNA repair, and healthy aging.

Company Overview

Niagen Bioscience Inc., formerly known as ChromaDex Corporation, operates in the life sciences tools and services sector. The company is based in Los Angeles, United States, and is listed on the Nasdaq stock exchange. As of May 1, 2025, Niagen Bioscience’s stock closed at $8, with a market capitalization of approximately $594.85 million. The company’s price-to-earnings ratio stands at 72.1, reflecting its growth potential in the NAD+ market.

Market Context

The announcement of Niagen IV’s expanded availability comes amidst growing interest in NAD+ supplements for their potential benefits in enhancing energy, longevity, and mitochondrial health. Competitors and related companies are also exploring NAD+ formulations, with products like Wonderfeel’s NMN supplements and NooCube’s NAD+ formulas gaining attention for their anti-aging and energy-boosting properties.

Niagen Bioscience’s strategic expansion aligns with the increasing demand for scientifically-backed NAD+ therapies, positioning the company as a key player in the health care sector focused on healthy aging solutions.